uniQure's Huntington's Gene Therapy Faces FDA Study Requirement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy QURE?
Source: Yahoo Finance
- Stock Price Plunge: uniQure's stock plummeted over 40% due to the FDA's request for additional studies, dropping from $15.63 on February 27 to $9.19 on March 2, resulting in a market cap of $613.6 million, indicating a severe loss of investor confidence in its AMT-130 gene therapy.
- FDA Study Requirement: During a meeting with the FDA, uniQure was mandated to conduct a prospective, randomized, double-blind, sham surgery-controlled study to provide sufficient evidence of effectiveness, which may delay the product's market entry and impact the company's long-term strategy.
- CEO's Commitment to Future: CEO Matt Kapusta stated that despite failing to align on a submission pathway, the company remains committed to engaging with the FDA for a scientifically grounded path forward, demonstrating ongoing support for patients and their families.
- Multiple Challenges Ahead: In addition to the Huntington's disease program, uniQure's Fabry disease program is also facing challenges, as the FDA has ordered a dosing pause due to safety concerns, further increasing the pressure on the company's R&D efforts and potentially affecting overall business development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 16.890
Low
33.00
Averages
49.88
High
70.00
Current: 16.890
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Criticism: On March 5 and 6, 2026, an FDA official labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially affecting the company's relationship with the FDA.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, with this omission contributing to a 49% stock drop in November 2025.
- Critical Deadline: Investors must apply to be the Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in lost opportunities for recovery, further impacting investor confidence and the company's reputation.
See More
Faruqi & Faruqi Investigates Investor Losses in UniQure
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against UniQure N.V., particularly for investors who purchased or acquired securities between September 24, 2025, and October 31, 2025, highlighting the firm's commitment to investor rights.
- Investor Contact Information: The firm encourages affected investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a strong focus on client service.
- Class Action Deadline: Faruq & Faruqi reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against UniQure is April 13, 2026, emphasizing the importance of timely action.
- Role of Securities Law Firm: As a leading national securities law firm, the investigation by Faruq & Faruqi could impact UniQure's reputation and stock price, prompting investors to stay informed about developments to protect their interests.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: On March 5 and 6, 2026, FDA officials publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly harm the company's reputation and stock price.
- Securities Class Action: Hagens Berman is investigating uniQure for failing to disclose interactions with the FDA during the class period from September 24 to October 31, 2025, potentially leading to investor losses and having profound implications for the company's legal and financial standing.
- Critical Deadline: Investors must apply to be Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in the loss of their claims, directly impacting their rights and protections as shareholders.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to assist in the investigation and influencing uniQure's future trajectory.
See More
Reminder for uniQure Shareholders on Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval for its pivotal study on Huntington's disease treatment, resulting in investor losses when the true information was revealed, highlighting significant transparency issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, urging investors to select qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
See More
uniQure Faces Class Action Lawsuit; Investors Encouraged to Claim
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks for the company.
- Allegation Details: The complaint alleges that uniQure made materially false and misleading statements during the class period, failing to disclose that the design of its Pivotal Study was not fully FDA approved, which could delay its BLA submission and impact the company's prospects.
- Investor Rights: Investors must apply by April 13, 2026, to be appointed as lead plaintiff, highlighting the potential impact of these legal challenges on the company's stock price and investor confidence.
- Legal Consultation Available: Bragar Eagel & Squire offers free consultations, allowing investors to contact attorneys via phone or email to understand their legal rights and potential claims.
See More
uniQure Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that the deadline to file lead plaintiff applications in the uniQure N.V. securities class action lawsuit is April 13, 2026, for those who purchased shares between September 24 and October 31, 2025, risking loss of claims if not filed on time.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of accelerated FDA approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data sufficient for a Biologics License Application, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, resulting in significant financial losses for investors.
- Legal Consultation Services: ClaimsFiler offers free legal consultation services, allowing investors to access information and connect with Kahn Swick & Foti, LLC lawyers to understand their legal options and protect their rights in the securities class action lawsuit.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Criticism: On March 5 and 6, 2026, an FDA official labeled uniQure's gene therapy candidate AMT-130 as a 'failed therapy,' accusing the company of conducting a 'distorted or manipulated comparison' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Surgery Requirement Controversy: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that the agency did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially affecting the company's relationship with the FDA.
- Legal Action Developments: The securities class action against uniQure alleges that the company failed to disclose that the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130, with this omission contributing to a 49% stock drop in November 2025.
- Critical Deadline: Investors must apply to be the Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in lost opportunities for recovery, further impacting investor confidence and the company's reputation.
See More
Faruqi & Faruqi Investigates Investor Losses in UniQure
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential claims against UniQure N.V., particularly for investors who purchased or acquired securities between September 24, 2025, and October 31, 2025, highlighting the firm's commitment to investor rights.
- Investor Contact Information: The firm encourages affected investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, demonstrating a strong focus on client service.
- Class Action Deadline: Faruq & Faruqi reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against UniQure is April 13, 2026, emphasizing the importance of timely action.
- Role of Securities Law Firm: As a leading national securities law firm, the investigation by Faruq & Faruqi could impact UniQure's reputation and stock price, prompting investors to stay informed about developments to protect their interests.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action
- FDA Rebuke: On March 5 and 6, 2026, FDA officials publicly criticized uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy,' alleging the company engaged in 'distorted or manipulated comparisons' in clinical studies, which could significantly harm the company's reputation and stock price.
- Securities Class Action: Hagens Berman is investigating uniQure for failing to disclose interactions with the FDA during the class period from September 24 to October 31, 2025, potentially leading to investor losses and having profound implications for the company's legal and financial standing.
- Critical Deadline: Investors must apply to be Lead Plaintiff in the class action by April 13, 2026, and failure to act promptly may result in the loss of their claims, directly impacting their rights and protections as shareholders.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to assist in the investigation and influencing uniQure's future trajectory.
See More
Reminder for uniQure Shareholders on Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that uniQure failed to fully disclose FDA approval for its pivotal study on Huntington's disease treatment, resulting in investor losses when the true information was revealed, highlighting significant transparency issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise, urging investors to select qualified legal counsel wisely.
- Investor Action Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they receive the necessary legal support and potential compensation in the class action.
See More
uniQure Faces Class Action Lawsuit; Investors Encouraged to Claim
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks for the company.
- Allegation Details: The complaint alleges that uniQure made materially false and misleading statements during the class period, failing to disclose that the design of its Pivotal Study was not fully FDA approved, which could delay its BLA submission and impact the company's prospects.
- Investor Rights: Investors must apply by April 13, 2026, to be appointed as lead plaintiff, highlighting the potential impact of these legal challenges on the company's stock price and investor confidence.
- Legal Consultation Available: Bragar Eagel & Squire offers free consultations, allowing investors to contact attorneys via phone or email to understand their legal rights and potential claims.
See More
uniQure Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that the deadline to file lead plaintiff applications in the uniQure N.V. securities class action lawsuit is April 13, 2026, for those who purchased shares between September 24 and October 31, 2025, risking loss of claims if not filed on time.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of accelerated FDA approval for their drug candidate AMT-130.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data sufficient for a Biologics License Application, uniQure's stock price plummeted from $67.69 to $34.29, a drop of over 49%, resulting in significant financial losses for investors.
- Legal Consultation Services: ClaimsFiler offers free legal consultation services, allowing investors to access information and connect with Kahn Swick & Foti, LLC lawyers to understand their legal options and protect their rights in the securities class action lawsuit.
See More
